Drug-coated balloon therapy to prevent restenosis after angioplasty in PAD
Official title: Drug Coated Balloon Peptide Delivery to Block Post-angioplasty Restenosis in PAD
Funded at Vanderbilt University · NIH-11396478 · Data updated 2026-11-12
A research project at Vanderbilt aims to develop safer, non-toxic balloon coatings to reduce re-narrowing after leg artery angioplasty in people with peripheral arterial disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 1, 2025 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $473,086 |
| NIH project number | 5R33HL181752-02 |
| Project ID | NIH-11396478 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with peripheral arterial disease undergoing angioplasty who would benefit from improved vessel patency and healing.
✕Less likely to help
Patients not undergoing angioplasty or those with different vascular conditions may not directly benefit.
What this research studies
Peripheral arterial disease can cause leg pain and even amputation. The study focuses on improving balloon angioplasty by using a drug-coated balloon that releases a non-cytotoxic coating to prevent restenosis without harming the vessel lining. Researchers will explore delivery of this coating from the balloon into the artery wall and assess its effects on healing and patency. The work builds on current clinical approaches but seeks a safer, more durable solution to keep arteries open longer.
Why it matters
Potential benefit: If successful, patients could experience fewer re-blockages and better long-term leg blood flow after angioplasty.
How similar studies have gone: Previous drug-coated balloon work reduces restenosis but uses cytotoxic drugs; this project aims for a safer, non-cytotoxic alternative.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.